| Similar Articles |
|---|
 |
The Motley Fool
October 12, 2009
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Here are seven companies that analysts see posting healthier bottom lines this week: Google... IBM... Abbott Labs... Baxter International... JPMorgan Chase... Goldman Sachs... Citigroup...   |
The Motley Fool
August 3, 2009
Rick Aristotle Munarriz |
7 Reasons Not to Worry This Week Not every company will be posting lower earnings this week. |
The Motley Fool
July 16, 2010
Rick Aristotle Munarriz |
7 Reasons to Worry About Next Week Let's go over a few of the blue chips and seemingly recession-proof companies predicted to post bottom-line slumps next week: Cintas... Goldman Sachs... Wells Fargo... TD AMERITRADE... Baxter... Eli Lilly... Safeway... |
The Motley Fool
October 21, 2010
Brian Orelli |
Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors. |
InternetNews
April 19, 2011 |
IBM Kicks Off First Quarter With Strong Results IBM exceeds expectations and raises outlook for the full year. |
InternetNews
January 19, 2010 |
IBM Blows Past Q4 Revenue, Earnings Projections Services and software businesses up, hardware down as the company ends the year strong. |
The Motley Fool
October 7, 2011
Rick Aristotle Munarriz |
4 Reasons to Worry About Next Week Let's go over a few of the names that are expected to go the wrong way on the bottom line next week: Bank of the Ozarks... Fairchild Semiconductor... JPMorgan... Winnebago... |
InternetNews
July 19, 2010 |
IBM Q2 Soars, Sees Mounting Recovery IBM topped profit estimates for its second quarter and displayed some optimism for the rest of the year. |
The Motley Fool
September 24, 2010
Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
The Motley Fool
September 28, 2009
Rick Aristotle Munarriz |
Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered. |
The Motley Fool
September 18, 2008
Selena Maranjian |
Yikes! What Happened to My Fund? Beware of high concentrations when you invest in sector funds. |
The Motley Fool
June 29, 2010
Brian Orelli |
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify. |
The Motley Fool
October 18, 2006
Brian Lawler |
Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note. |
The Motley Fool
January 27, 2011
Brian Orelli |
Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out. |
The Motley Fool
April 20, 2011
Cindy Johnson |
Don't Miss Out on This Underappreciated Tech Winner IBM is planning the growth ... and outgrowing the plan. |
The Motley Fool
June 5, 2006
Brendan Mathews |
IBM: Big Value at Big Blue The stock of the traditional technology powerhouse is looking cheap. |
The Motley Fool
January 19, 2012
Tim Beyers |
What to Expect From IBM Today Will IBM put up big gains? |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
December 29, 2010
Cindy Johnson |
IBM Is Well-Positioned for the New New Economy This aging tech giant could be a big winner. |
The Motley Fool
January 23, 2007
Ralph Casale |
Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note. |
The Motley Fool
January 8, 2010
Rick Aristotle Munarriz |
7 Reasons to Worry About Next Week Let's go over a few of the blue chip companies where analysts see the arrows pointing down on the bottom line next week: Shuffle Master... Bank of the Ozarks... SUPERVALU... Linear Technology... Infosys... Great Atlantic & Pacific Tea... Audiovox... |
The Motley Fool
August 11, 2011
Cindy Johnson |
2 Tech Greats I'm Looking to Buy on the Dip These great tech companies should do well in any economy. |
The Motley Fool
January 18, 2012
Robert Eberhard |
Regional Bank Earnings Roundup Regional banks join the banks of the "too big to fail" variety in presenting earnings this week. |
BusinessWeek
January 29, 2007
Michael Arndt |
Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade. |
The Motley Fool
November 3, 2011
Dan Caplinger |
Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection. |
The Motley Fool
March 16, 2011
Cindy Johnson |
Hidden in Plain Sight, Wall Street Discovers a Tech Gem Misunderstood and underappreciated for years, IBM is starting to get credit for transforming itself over the last couple of decades into a well-oiled, cash-generation machine. |
The Motley Fool
April 22, 2010
Brian Orelli |
Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care. |
The Motley Fool
February 22, 2010
Rick Aristotle Munarriz |
4 Dividend Stocks Showing You the Money Companies with growing yields can make you rich in more ways than the obvious. |
The Motley Fool
October 12, 2010
Jim Royal |
This Stock Could Be an Easy Double Special situation investing is a good place to be. Crown Media -- has just executed a recapitalization, a special situation that makes its profitability more apparent to investors. |
InternetNews
April 19, 2010 |
IBM Earnings Up on IT Spending Boost Across-the-board growth for the IT bellwether signals returning strength for the sector. |
The Motley Fool
April 17, 2009
Robert Steyer |
The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity. |
The Motley Fool
November 15, 2011
Dan Caplinger |
Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares. |
The Motley Fool
February 23, 2004
Brian Gorman |
Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division. |
The Motley Fool
April 20, 2006
Stephen D. Simpson |
Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough? |
The Motley Fool
July 29, 2010
Brian Orelli |
Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company. |
The Motley Fool
October 19, 2005
Stephen D. Simpson |
Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock. |
The Motley Fool
January 16, 2012
John Grgurich |
IBM Goes Nuclear on Computing In a single, brilliant stroke of technological innovation, IBM throws Moore's Law out the atomic window. |
The Motley Fool
August 4, 2010
Matt Koppenheffer |
How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale? |
The Motley Fool
January 19, 2011
Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
The Motley Fool
December 28, 2006
Tom Taulli |
Previewing 2007: IBM IBM's stock seems attractive, as it has room to catch up with the valuations of other big-cap tech companies. |
The Motley Fool
July 13, 2005
Stephen D. Simpson |
Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history. |
InternetNews
October 16, 2007
Larry Barrett |
IBM Nips 3Q Estimates But Hardware Sales Slip Some of IBM's server and mainframe units suffered through a lackluster quarter but the company said it's still on track to meet its lofty earnings targets for this year and through 2010. |
The Motley Fool
April 26, 2006
Tim Beyers |
Big Blue's Big Buy IBM bumps its dividend 50% and boosts share buybacks. This move has all the markings of smart capital allocation that's likely to be rewarding for patient investors. |
The Motley Fool
July 28, 2011
Cindy Johnson |
Add It All Up: IBM Is Cheap Diversified businesses that are tough to value can be great values. |
The Motley Fool
January 18, 2005
Stephen D. Simpson |
Abbott Still Looks Healthy Never a too-big roaring growth stock or a too-small low-growth behemoth, the medical products company seems just right as it dependably keeps on performing for investors. |
The Motley Fool
October 14, 2009
Brian Orelli |
Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out. |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
The Motley Fool
April 11, 2009
Rick Aristotle Munarriz |
The Fool's Look Ahead Banks, brokers, and baby shampoo will decorate the week that lies ahead. |
BusinessWeek
September 22, 2003 |
This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories. |
The Motley Fool
May 21, 2010
Brian Orelli |
Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea. |
